HC Wainwright Begins Coverage on Tvardi Therapeutics (NASDAQ:TVRD)

Equities research analysts at HC Wainwright initiated coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a report released on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 211.42% from the stock’s previous close.

Several other research analysts have also recently commented on TVRD. BTIG Research reissued a “buy” rating and set a $15.00 price target on shares of Tvardi Therapeutics in a research report on Wednesday, April 1st. Wall Street Zen cut Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.17.

Tvardi Therapeutics Stock Performance

NASDAQ TVRD opened at $2.89 on Monday. The stock has a 50-day simple moving average of $3.36 and a 200 day simple moving average of $3.79. The company has a market capitalization of $27.11 million, a PE ratio of -0.93 and a beta of 0.33. Tvardi Therapeutics has a 12 month low of $2.75 and a 12 month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.08). As a group, sell-side analysts predict that Tvardi Therapeutics will post -2.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tvardi Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TVRD. XTX Topco Ltd bought a new stake in Tvardi Therapeutics during the 4th quarter worth $55,000. Quadrature Capital Ltd bought a new stake in Tvardi Therapeutics during the 4th quarter worth $90,000. Russell Investments Group Ltd. grew its position in Tvardi Therapeutics by 1,351.5% during the 4th quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock worth $69,000 after acquiring an additional 14,866 shares during the last quarter. Squarepoint Ops LLC grew its position in Tvardi Therapeutics by 534.3% during the 4th quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock worth $223,000 after acquiring an additional 43,619 shares during the last quarter. Finally, Arax Advisory Partners grew its position in Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after acquiring an additional 6,173 shares during the last quarter. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.